BioAge Labs (NASDAQ:BIOA) lowered to strong sell rating by Wall Street Zen. September 5, 2026 Key points. * Wall Street Zen downgraded BioAge Labs to "strong sell" from "sell," although broader analyst sentiment remains "Moderate Buy," with six buy ratings and one sell rating. * Analysts' consensus price target is $36.57, but individual targets vary widely from $21 to $50; the stock opened at $9.59 and has traded between $4.58 and $25.95 over the past year. * BioAge reported a quarterly loss of $0.58 per share, better than the expected $0.65 loss, on $2.45 million in revenue. The company remains deeply unprofitable, with a negative net margin of 912.26%. * Five stocks to consider instead of BioAge Labs. BioAge Labs (NASDAQ:BIOA - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports. A number of other equities research analysts also recently weighed in on the stock. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st. BTIG Research restated a "buy" rating and set a $40.00 price objective on shares of BioAge Labs in a research note on Monday, August 3rd. Roth Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Finally, Needham & Company LLC cut their target price on BioAge Labs from $50.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, BioAge Labs currently has an average rating of "Moderate Buy" and a consensus price target of $36.57. BioAge Labs stock performance. BIOA stock opened at $9.59 on Friday. The company's 50-day simple moving average is $16.50 and its 200 day simple moving average is $17.82. BioAge Labs has a 52 week low of $4.58 and a 52 week high of $25.95. The company has a market capitalization of $440.18 million, a PE ratio of -4.03 and a beta of 0.94. BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, analysts forecast that BioAge Labs will post -2.45 EPS for the current year. Institutional investors weigh in on BioAge Labs. Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of BioAge Labs in the 2nd quarter valued at $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs during the 2nd quarter worth $52,597,000. Janus Henderson Group PLC lifted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock valued at $30,573,000 after buying an additional 150,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock valued at $9,709,000 after buying an additional 93,694 shares in the last quarter. About BioAge Labs. BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations. Discover more Stock split calculator Financial News Stock profit calculator At the core of BioAge's operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider BioAge Labs, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAge Labs wasn't on the list. While BioAge Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Did Novo's phase 3 flop kill the inflammation hypothesis in heart disease? While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events. Published Aug. 10, 2026 By Kelly Bilodeau When Novo Nordisk recently reported that its experimental heart drug ziltivekimab failed to reduce the risk of heart attacks and strokes in a late-stage trial, the market reaction was swift. Novo's stock fell as much as 10%, while shares of several other companies also tumbled amid fears the results cast doubt on whether targeting inflammation could reduce the risk of serious cardiovascular events. The phase 3 Zeus trial enrolled over 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation, following participants for up to four years. Although ziltivekimab produced the expected biological effect, lowering interleukin-6 and high-sensitivity C-reactive protein (hsCRP), it failed to reduce major adverse cardiovascular events (MACE) - cardiovascular death, nonfatal heart attack or stroke - compared with placebo. While investors may have been spooked by the failure, it didn't necessarily mark a death knell for the inflammation hypothesis, according to William Blair analyst Andy Hsieh. Instead, he said, the result may say more about IL-6 inhibition (and hsCRP as a surrogate marker) than it does about inflammation itself. "In our view, the bearish read-through is more limited to hsCRP's surrogacy for cardio protection in the context of IL-6 inhibition," he said in an email. The better approach to reducing cardiovascular events might involve targeting a different protein, interleukin-1beta (IL-1β). In Novartis' Cantos trial, for instance, a 150-mg dose of the drugmaker's IL-1β inhibitor Ilaris significantly reduced recurrent cardiovascular events compared with placebo. "We have validation that IL-1beta inhibition leads to MACE reduction," Hsieh said. "This effect was dependent on hsCRP reduction magnitude (2 mg/L cutoff). So I wouldn't say the data invalidates the inflammatory hypothesis in its entirety." The Novo readout's ripple effect. While the inflammation hypothesis may not be dead, Novo's phase 3 results could dampen enthusiasm for NLRP3 inhibitors, a broader anti-inflammatory approach that can also affect IL-6 expression. For instance, BioAge Labs' shares fell roughly 60% in premarket trading after Novo's Zeus readout, according to the William Blair note. BioAge is testing BGE-102 in the phase 2 Quell-Cv trial in patients at elevated cardiovascular risk and plans a phase 1b/2a study in diabetic macular edema. "Despite plans to examine BGE-102 in ophthalmology indications, we believe the approach remains high-risk and difficult to build an investment thesis around," Hsieh and William Blair colleagues wrote in a biotech note. Neumora, which is developing the preclinical NLRP3 inhibitor NMRA-215 for obesity and cardiometabolic disease, saw a 5% premarket drop after the ziltivekimab failure. William Blair sees less read-through to the program, however, because NLRP3 inhibition acts more broadly than IL-6 blockade and NMRA-215's lead indication is obesity. Ziltivekimab's story may not be over. Novo acquired the drug in its 2020 acquisition of Corvidia Therapeutics, and it remains in two additional phase 3 trials: Hermes in heart failure and Artemis in patients following an acute heart attack. Readouts for those trials are expected in the first half of 2027. "While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease," said Martin Holst Lange, Novo's executive vice president, chief scientific officer and head of research and development, in a press release. "The study provides important scientific evidence that will inform its ongoing cardiovascular research and the development of treatments for patients who continue to face substantial unmet need.